SWOG clinical trial number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

64% Accrual
Accrual
64%
Closed
Phase
64% Accrual
Accrual
64%
Abbreviated Title
Sacituzumab Govitecan for HER2-Neg Breast Cancer and Brain Metastases
Status Notes
Status Notes: Permanently Closed to Accrual 04/07/2025, 2:00 pm CT

Activated
12/15/2020
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer

Treatment

sacituzumab govitecan

Other Clinical Trials

S2206
SWOG Clinical Trial Number

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
17% Accrual
Accrual
17%
Open
Phase
S2212
SWOG Clinical Trial Number

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)
Breast Cancer
Activated
07/21/2023
25% Accrual
Accrual
25%
Open
Phase
CTSU/NRG-BR007
SWOG Clinical Trial Number

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase